РЕЗИСТЕНТНОСТЬ К ПРОТИВОВИРУСНЫМ ПРЕПАРАТАМ ПРИ ХРОНИЧЕСКОМ ГЕПАТИТЕ В


Цитировать

Полный текст

Аннотация

Современные подходы к лечению хронического гепатита В как правило предполагают назначение длительных курсов противовирусных препаратов из группы аналогов нуклеозидов и нуклеотидов, что часто сопровождается развитием лекарственной устойчивости. В обзоре рассматриваются механизмы ее возникновения, факторы, способствующие развитию резистентности к лекарствам, описываются типы мутаций устойчивости и частота их возникновения при лечении современными противовирусными препаратами. Подчеркивается важность использования в клинической практике современных молекулярных методов контроля эффективности лечения. Обсуждаются вопросы профилактики развития резистентности и тактика лечения пациентов с хроническим гепатитом В в случае ее возникновения.

Об авторах

В П Чуланов

ФГУН Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора, Москва

ФГУН Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора, Москва

V Chulanov

Список литературы

  1. Okamoto H, Imai M, Kametani M, et al. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987;57:231-6.
  2. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989;170:595-7.
  3. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-402.
  4. Chong Y, Stuyver L, Otto MJ, et al. Mechanism of antiviral activities of 30-substituted L-nucleosides against 3TC resistant HBV polymerase: a molecular modelling approach. Antivir Chem Chemother 2003;14:309-19.
  5. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-65.
  6. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593-608.
  7. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49:174-84.
  8. European Association For The Study Of The Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
  9. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
  10. Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int 2009;29:108-15.
  11. Yuen MF, Fung J, Wong DK, et al. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009;9:256-64.
  12. Hulgan T, Haas DW: Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. J Infect Dis 2006;194:1471-4.
  13. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
  14. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
  15. Lai CL, Dienstag J, Schiff E, et al. Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B. Clin Infect Dis 2003;36:687-96.
  16. Yuen MF, Chow DH, Tsui K, et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther 2005;21:841-9.
  17. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007;13:4085-90.
  18. Chang ML, Chien RN, Yeh CT, et al. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 2005;43:72-7.
  19. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007;14:29-36.
  20. Zoulim F, Poynard T, Degos F, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278-88.
  21. Kobayashi M, Suzuki F, Akuta N, et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 2006;78:1276-83.
  22. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-12.
  23. Osiowy C, Villeneuve JP, Heathcote EJ, et al. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 2006;44:1994-7.
  24. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-90.
  25. Westland C, Delaney W 4th, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003;125:107-16.
  26. Zollner B, Petersen J, Puchhammer-Stockl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004;39:42-50.
  27. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-4.
  28. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91.
  29. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008;2:147-51.
  30. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696.
  31. Lai CL, Gane E, Liaw YF, et al. Globe Study Group Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576-88.
  32. Liaw YF, Gane E, Leung N, et al. GLOBE Study Group 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136(2):486-95.
  33. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
  34. Marcellin P, M Buti, Z Krastev, et al. Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102); Preliminary Analysis. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston. 2009.
  35. Heathcote EJ, Gane, RA De Man, at al. Three Years of Tenofovir Disoproxil (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103), Preliminary Analysis. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston. 2009.
  36. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
  37. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. J Hepatol 2009;50:10.
  38. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-93.
  39. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132:1574-85.
  40. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
  41. Seifer M, Patty A, Serra I, et al. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009;81:147-55.
  42. Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
  43. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-55.
  44. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-55.
  45. Delaney WE 4th, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003;77:11833-41.
  46. Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000;33:469-75.
  47. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-507.
  48. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008;47:1473-82.
  49. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12.
  50. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7.
  51. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 2006;44:593-606.
  52. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-98.
  53. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-12.
  54. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008;13:381-8.
  55. Curtis M, Zhu Y, Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 2007;196:1483-6.
  56. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-34.
  57. Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-7.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах